BPGbio Appoints Former Oxford Innovation Chief Chas Bountra as CSO to Advance Mitochondrial Therapeutics Pipeline
Key Insights
BPGbio (search) has appointed Chas Bountra, Ph.D., former Oxford Pro-Vice Chancellor for Innovation and ex-GSK Head of Biology, as Executive Vice President and Chief Scientific Officer to lead the company's R&D efforts.
Dr. Bountra, who previously chaired BPGbio (search)'s Scientific Advisory Board since 2017, will accelerate the company's advanced-stage pipeline including lead asset BPM31510, which is advancing toward Phase 3 trials for Primary CoQ10 Deficiency (search).
The appointment strengthens BPGbio (search)'s translational capabilities as the company expands its causal AI platform NAi across oncology, rare diseases, and neurology programs.
BPGbio (search), a clinical-stage biopharma company specializing in AI-powered mitochondrial therapeutics, has appointed Chas Bountra, Ph.D., as Executive Vice President and Chief Scientific Officer. The appointment marks a strategic expansion of Dr. Bountra's role from his previous position as Chair of BPGbio's Scientific Advisory Board, which he has held since 2017.
Leadership Transition Strengthens Scientific Strategy
Dr. Bountra brings extensive experience in translational science and drug discovery to his new role. He previously served as Pro-Vice Chancellor for Innovation at the University of Oxford and as Head of Impact and Innovation in the Nuffield Department of Clinical Medicine, where he held the position of Professor of Translational Medicine. His academic leadership included directing the Structural Genomics Consortium (SGC), which he helped establish as one of the world's most influential public-private partnerships for open science and target validation.
"I am keen to harness the talent, the unique resources and platforms, and some truly novel scientific insights and therapeutic approaches, to accelerate new treatments for patients living with rare diseases, neurodegeneration or life threatening cancers," said Dr. Bountra. "I believe, the company's lead asset BPM31510 is going to transform the lives of many tens of millions of patients. My goal is to help fast track it through late-stage development in many rare and common diseases."
Proven Track Record in Drug Development
Before joining Oxford in 2008, Dr. Bountra served as Vice President and Head of Biology at GlaxoSmithKline (GSK), where he contributed to the identification of more than 40 clinical candidates across gastrointestinal, inflammatory, and neuropsychiatric diseases. More than 20 of these programs advanced into patient studies, with several achieving proof-of-concept data and progressing to late-stage development. His notable contributions include playing a key role in developing the first approved treatment for irritable bowel syndrome (search), Alosetron, and demonstrating the anti-emetic potential of neurokinin NK1 (search) antagonists in preclinical and clinical studies.
Advanced Pipeline and AI Platform Integration
BPGbio (search)'s lead program, BPM31510, is advancing toward a Phase 3 clinical trial for Primary CoQ10 Deficiency (search) (PCQD), alongside ongoing mid to late-stage clinical programs in oncology, including Phase 2b trials in Glioblastoma (search) (GBM). The company's broader pipeline emerges from its causal AI-driven discovery platform, NAi®, which integrates large-scale biobank and patient-derived multiomics data with Bayesian causal inference to uncover actionable biology and guide therapeutic development with greater precision.
"Chas has been a trusted partner to BPGbio (search); as Chair of our SAB, he has helped shape the direction of our platform and pipeline," said Niven R. Narain, Ph.D., President and CEO of BPGbio. "As we continue advancing programs like BPM31510 and expanding the reach of our causal AI platform across oncology, rare diseases, and neurology, his transition into the role of CSO strengthens our translational engine and supports the next phase IND and NDA pathways."
Focus on Mitochondrial Biology
BPGbio (search) operates as a biology-first AI-powered biopharma company focused on mitochondrial biology and protein homeostasis. Headquartered in greater Boston, the company leverages its NAi Interrogative Biology® platform and one of the world's largest clinically annotated biobanks to develop its pipeline spanning oncology, rare diseases, and neurology. Dr. Bountra's familiarity with the NAi platform positions him to drive near-term translation across second-generation oncology and rare disease assets.